Since 2001, ABC2 has awarded more than 100 grants totaling over $20 million to world-renowned researchers and physician-scientists from 54 institutions. We think strategically about our research investments. Learn more about some of our featured projects by using the filter below to explore our six basic research areas.

A Fast-Paced Search for Targeted DIPG Therapies

Title: Rapid preclinical development of a targeted clinical therapy for DIPG
Investigators: Charles Keller and Paul Spellman
Grantees: Oregon Health & Science University (+ 7 others in consortium)

Targeting Lower-Grade Gliomas

Title: Developing Novel Approaches to Target Glioma
Investigator: Hai Yan
Grantee: Duke University

Mutations in two specific genes, IDH1 and IDH2, are very common in lower-grade and secondary gliomas.  Pinpointing how these mutations are related to brain tumor growth—and finding drugs that counteract their effects—are thus critical goals for treating the many brain cancer patients whose tumors bear these genetic changes.